Silence Therapeutics (NASDAQ:SLN) Given “Buy” Rating at Chardan Capital

Silence Therapeutics (NASDAQ:SLN)‘s stock had its “buy” rating reiterated by Chardan Capital in a report issued on Tuesday,Benzinga reports. They presently have a $55.00 price target on the stock.

Several other equities analysts have also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a report on Monday. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. BMO Capital Markets reissued an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. Morgan Stanley reaffirmed an “overweight” rating and issued a $49.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, October 8th. Finally, Jefferies Financial Group initiated coverage on shares of Silence Therapeutics in a research report on Tuesday, September 3rd. They set a “buy” rating and a $40.00 target price for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Silence Therapeutics currently has an average rating of “Buy” and a consensus target price of $57.20.

Silence Therapeutics Stock Performance

NASDAQ:SLN opened at $6.45 on Tuesday. The company has a market cap of $193.04 million, a price-to-earnings ratio of -4.11 and a beta of 1.05. The stock’s fifty day moving average price is $14.19 and its two-hundred day moving average price is $17.32. Silence Therapeutics has a 52-week low of $5.81 and a 52-week high of $27.72.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Legato Capital Management LLC acquired a new stake in Silence Therapeutics in the second quarter worth $376,000. Custom Index Systems LLC bought a new stake in shares of Silence Therapeutics in the 2nd quarter valued at $282,000. Nicholas Investment Partners LP acquired a new stake in Silence Therapeutics during the 2nd quarter worth $2,859,000. First Turn Management LLC bought a new position in Silence Therapeutics during the second quarter worth about $10,209,000. Finally, Lombard Odier Asset Management USA Corp grew its stake in Silence Therapeutics by 0.7% in the second quarter. Lombard Odier Asset Management USA Corp now owns 2,405,998 shares of the company’s stock valued at $45,714,000 after acquiring an additional 17,086 shares during the period. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.